Semaglutide for Metabolic Dysfunction–Associated Steatohepatitis
1. 系统已在2025-07-21 16:06:53对应助文件进行删除
2. 如有需要请重新发布求助信息
注: 所有应助的资源仅供学习交流使用, 不得违反相关法律法规
DOI:
文献链接:
其他信息:
TG Simon
New England Journal of Medicine, 2025
Mass Medical Soc
Metabolic dysfunction–associated steatotic liver disease (MASLD) is a leading cause of chronic liver disease that affects more than 30% of adults worldwide. 1 Up to one third of patients with MASLD have progressive steatohepatitis (MASH) and fibrosis, which can lead to cirrhosis and death. 2 MASH is also associated with an excess risk of cardiovascular disease, a finding that underscores the importance of simultaneously addressing cardiometabolic risk factors in the treatment of this disease. 2 Currently, the only medication …
